We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Tumor Painting Helps Fight Cancer

By HospiMedica staff writers
Posted on 31 Jul 2007
A peptide-derived paint that illuminates cancerous cells could help surgeons see where a tumor begins and ends more precisely, says a new study.

Researchers at Seattle Children's Hospital Research Institute (WA, USA) and the Fred Hutchinson Cancer Research Center (Seattle, WA, USA) developed the paint, a scorpion-derived peptide called chlorotoxin that is linked to Cy5.5, a fluorescent molecular beacon that emits photons in the near infrared spectrum. More...
Chlorotoxin:Cy5.5 activates within hours and it begins binding to cancer cells within minutes; the signal lasts for 14 days. Cy5.5 can identify tumors with as few as 2000 cancer cells, making it 500 times more sensitive than magnetic resonance imaging (MRI). In mouse models, the team demonstrated that they could light up brain tumors as small as 1 millimeter in diameter without lighting up the surrounding normal brain tissue; while in a prostate cancer model as few as 200 cancer cells traveling in a mouse lymph channel could be detected.

This illumination gives surgeons a better chance of removing all of the cancerous cells during surgery without injuring surrounding healthy tissue. This is particularly significant in the brain, where approximately 80% of malignant cancers recur at the edges of the surgical site. The study was published in the July 15, 2007, issue of Cancer Research.

"My greatest hope is that tumor paint will fundamentally improve cancer therapy,” said senior author James M. Olson, M.D., Ph.D. "By allowing surgeons to see cancer that would be undetectable by other means, we can give our patients better outcomes.”

The researchers believe that Chlorotoxin:Cy5.5 has the potential to be used in the future as a non-invasive screening tool for early detection of skin, cervical, esophageal, colon and lung cancers. It is also useful in identifying positive lymph nodes, which could mean a significant advancement for breast, prostate, and testicular cancers.


Related Links:
Seattle Children's Hospital Research Institute
Fred Hutchinson Cancer Research Center

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammography System (Analog)
MAM VENUS
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.